Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPIAL TRIAL: Esaxerenone vs Amlodipine for Albuminuria Reduction in Hypertensive Heart Failure Patients
jRCTs051210066Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of esaxerenone in hypertension (HTN), heart failure (HF) and albuminuria (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in UACR ratio at 24 weeks. Started Aug 2021; status: completed.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)heart failure (HF)albuminuria
Beyond the preview
Go deeper on jRCTs051210066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210066.